Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lothar Mueller"'
Autor:
Arndt Vogel, Arno Schad, M.P. Lutz, Peter C. Thuss-Patience, Markus Moehler, Florian Lordick, Sylvie Lorenzen, E. Van Cutsem, S.-E. Al-Batran, Maria Alsina, Baruch Brenner, Julia Slotta-Huspenina, Annett Maderer, Wolfgang Eisterer, Kersten Borchert, Lothar Mueller, Richard Greil, Johannes Meiler, R.D. Hofheinz, Thomas J. Ettrich
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 31(2)
Background Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor receptor (EGFR) with panitumumab (P); chemotherapy enhanced overall survival (OS) in ad
Autor:
Florian Lordick, Salah-Eddin Al-Batran, Eric Van Cutsem, Baruch Brenner, Wolfgang Eisterer, Markus Moehler, Thomas J. Ettrich, Arndt Vogel, Arno Schad, Kersten Borchert, Lothar Mueller, Julia Slotta-Huspenina, Ralf-Dieter Hofheinz, Richard Greil, Manfred P. Lutz, Maria Alsina, Peter C. Thuss-Patience, Annett Maderer, Sylvie Lorenzen, Johannes Meiler
Publikováno v:
SSRN Electronic Journal.
Background: Advanced unresectable esophageal squamous cell cancer (ESCC) is treated with palliative chemotherapy of cisplatin and 5-fluorouracil (CF). Targeting epidermal growth factor receptor (EGFR) with antibodies panitumumab (P) or cetuximab with
Autor:
Richard Greil, Kersten Borchert, Lothar Mueller, E. Van Cutsem, Johannes Meiler, Markus Moehler, Baruch Brenner, Ralph Keller, F. Longo Muñoz, Thomas J. Ettrich, Peter C. Thuss-Patience, A. Karatas, J. Hecker, M. Alsina, R.D. Hofheinz, Julian Larcher-Senn, S.-E. Al-Batran, Manfred P. Lutz, Arndt Vogel, Sylvie Lorenzen, Annett Maderer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cc0e0e7fb33ad84e9c786430d954684
https://www.ncbi.nlm.nih.gov/pubmed/32176989
https://www.ncbi.nlm.nih.gov/pubmed/32176989
Autor:
Baruch Brenner, Kersten Borchert, Ralph Keller, Lothar Mueller, Julian Larcher-Senn, Thomas J. Ettrich, Maria Alsina, Federico Longo, Arndt Vogel, Eric Van Cutsem, Peter C. Thuss-Patience, Manfred P. Lutz, Markus Moehler, Sylvie Lorenzen, Ralf Hofheinz, Salah-Eddin Al-Batran, A. Karatas, Johannes Meiler, Richard Greil
Publikováno v:
Journal of Clinical Oncology. 35:4011-4011
4011 Background: Most ESCC pts have advanced disease at time of diagnosis. Chemotherapy (CTX) is used to improve quality of life (QoL) and overall survival (OS), but still with limited impact. Prior studies suggested increased efficacy of EGFR antibo
Autor:
Radoslav Chekerov, Eva-Maria Grischke, Christian M. Kurbacher, Petra Krabisch, Jalid Sehouli, Peter Klare, Elena Ioana Braicu, Lothar Mueller, Jochem Potenberg, Georg Heinrich, Pauline Wimberger
Publikováno v:
Journal of Clinical Oncology. 35:5558-5558
5558 Background: For ovarian cancer (OC) patients with platinum-sensitive recurrence the addition of new biologic agents to chemotherapy may improve survival. Panitumumab is a fully human monoclonal antibody specific to the epidermal growth factor re
Autor:
Eric Van Cutsem, Anja Klein, Sylvie Lorenzen, Salah-Eddin Al-Batran, Ralf Hofheinz, Baruch Brenner, Josep Tabernero, Markus Moehler, Kersten Borchert, Lothar Mueller, Ralph Keller, Richard Greil, Ingo Ringshausen, Peter C. Thuss-Patience, Manfred P. Lutz, A. Karatas, Anne L Kranich, Ullrich Graeven
Publikováno v:
Journal of Clinical Oncology. 31:TPS4158-TPS4158
TPS4158 Background: More than 50% of pts with esophageal cancer have locally advanced or metastatic disease at the time of initial diagnosis. For this group chemotherapy is increasingly used intending local and distant tumor control, improvement of q